Heart failure & cardiomyopathies

Echocardiographic Haemodynamic Monitoring in the Context of HeartMate 3™ Therapy: A Systematic Review

ESC Heart FailPublished Systematic review

Authors' conclusion

Aortic regurgitation still seems to be a prevalent and potentially significant finding.

Study context

Population
Patients on HeartMate 3 (HM3) durable mechanical circulatory support9 studies
Outcome
Valvular regurgitation and RV dysfunction prevalence
Follow-up
≈12 months of support
Methodological detailsPRISMA 2020, Searches August 2023 in PubMed, Embase, Google Scholar, 8 cohort studies and 1 cross-sectional study, Quality: Newcastle-Ottawa Scale (NOS) for cohort studies, PCAI for cross-sectional studies
  • PRISMA 2020
  • Searches August 2023 in PubMed, Embase, Google Scholar
  • 8 cohort studies and 1 cross-sectional study
  • Quality: NOS for cohort studies, PCAI for cross-sectional studies

Pooled result

As reported in the abstract

approximately 12 months of support

Aortic regurgitation (AR) prevalence (n = 3 studies; heterogeneity)

33.5%

Δ 33%

Mitral regurgitation (MR) prevalence (2 studies; good consistency; no significant change over time)

15.0%

Δ 0.8%

Tricuspid regurgitation (TR) prevalence (n = 2 studies; fair consistency; statistically un-confirmed trend of increase over time)

28.5%

Δ 8.3%

Further pooled results

OutcomeHR (95% CI)
Death and HF readmission, significant ARvs none (one study)Cumulative incidence3.42 (1.48–8.76)

Survival free from heart failure (HF) readmission, worsening AR (second study)

HR (95% CI)P value
Worsening AR59% vs. 89%5.18 (1.07–25.0)P = 0.023

Cardiac- and non-cardiac-related hospitalizations by AR (third study) · 12 months follow-up

No differences

Original publication

Echocardiographic Haemodynamic Monitoring in the Context of HeartMate 3™ Therapy: A Systematic Review. ESC Heart Fail. Published 23 March 2024. doi:10.1002/ehf2.14759

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.